Stock Analysis
- Ireland
- /
- Healthcare Services
- /
- ISE:UPR
Uniphar First Half 2024 Earnings: EPS: €0.056 (vs €0.055 in 1H 2023)
Uniphar (ISE:UPR) First Half 2024 Results
Key Financial Results
- Revenue: €1.37b (up 10% from 1H 2023).
- Net income: €15.4m (up 2.4% from 1H 2023).
- Profit margin: 1.1% (down from 1.2% in 1H 2023). The decrease in margin was driven by higher expenses.
- EPS: €0.056 (up from €0.055 in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Uniphar Earnings Insights
Looking ahead, revenue is forecast to grow 4.2% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Healthcare industry in Europe.
Performance of the market in Ireland.
The company's shares are up 2.2% from a week ago.
Valuation
Following the latest earnings results, Uniphar may be undervalued based on 6 different valuation benchmarks we assess. Discover what analysts are forecasting and how the current share price shapes up by clicking here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ISE:UPR
Uniphar
Operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally.